ACU234 / Acumen Pharma - LARVOL DELTA

Development and Characterization of Novel Antibodies Targeting Amyloid Beta Oligomers with High Selectivity (GlobeNewswire) - "Researchers used SPR to measure antibody affinity and selectivity of these novel anti-AβO monoclonal antibodies (mAbs) for AβOs compared to monomers (Aβ1-28 and Aβ1-40). The study identified three novel AβO mAbs of interest, with ACU234 demonstrating notable selectivity – approximately 21,000-fold greater affinity for oligomeric versus monomeric Aβ. ACU234 underwent further evaluation using both in vitro and in vivo models of target engagement, including staining human brain samples from AD and controls compared to known Aβ mAbs, and injection into ARTE10 transgenic (Tg) mice to assess brain localization....Further work is needed to characterize ACU234 and explore its potential as an AβO-targeting therapeutic."

Preclinical • Alzheimer's Disease